SCHEMBL3112398

SCHEMBL3112398

COc1ccc(Cn2nc(C)c3c(Oc4ccc(-c5cnc(Nc6ccc(F)cc6)n(C)c5=O)cc4F)ccnc32)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 16/20 0.60
MST1R Q04912 5/20 0.60
KDR P35968 4/20 0.60
HGF P14210 4/20 0.52
RPS6KB1 P23443 2/20 0.52
TEK Q02763 2/20 0.52
BTK Q06187 2/20 0.52
JAK2 O60674 1/20 0.52
EGFR P00533 1/20 0.52
FLT1 P17948 1/20 0.52
FGFR2 P21802 1/20 0.52
FLT4 P35916 1/20 0.52
AURKA O14965 1/20 0.40
RPS6KA5 O75582 1/20 0.40
LCK P06239 1/20 0.40
PIM1 P11309 1/20 0.40
MAPK9 P45984 1/20 0.40
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3109429 0.94 MET (0.60) METMST1RKDRHGFRPS6KB1
SCHEMBL3109858 0.90 MET (0.58) METMST1RKDRHGFRPS6KB1
SCHEMBL3106815 0.87 MET (0.59) METMST1RKDRHGFRPS6KB1
SCHEMBL3095640 0.87 MET (0.45) METMST1RKDRHGFRPS6KB1
SCHEMBL3095637 0.82 MET (0.41) METMST1RKDRHGFRPS6KB1
SCHEMBL3101384 0.79 MET (0.53) METMST1RKDRHGFRPS6KB1
SCHEMBL3105978 0.79 NR3C1 (0.41) METMST1RKDRHGFUSP2
SCHEMBL3109382 0.78 MET (0.66) METMST1RKDRHGFRPS6KB1
SCHEMBL2855807 0.76 MET (1.00) METMST1RKDRHGFRPS6KB1
SCHEMBL3112710 0.75 MET (0.60) METKDRLCKCYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2010-10-07 US disclosed
US-7723330-B2 Heterobicyclic pyrazole compounds and methods of use ARRAY BIOPHARMA INC. (US) 2010-05-25 US disclosed
EP-2001880-A2 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE Array Biopharma, Inc. (US) 2008-12-17 EP disclosed
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use GENENTECH, INC. 2007-10-11 US disclosed
WO-2007103308-A2 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ROR1, CYP11B1, CYP11B2 MET 357/4885MST1R 642/4885KDR 807/4885
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use ROR1, CYP11B1, CYP11B2 MET 357/4885MST1R 642/4885KDR 807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.